Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Add as a preferred source on Google
BILLERICA, Mass., April 12, 2018 -- ConforMIS, Inc. (NASDAQ:CFMS) announced today that it will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2018. To participate in the conference call, please call 877-809-6331 (or 615-247-0224 for international) and use conference ID number 1695267.
The conference call will be hosted by Mark Augusti, President and Chief Executive Officer, and Paul Weiner, Chief Financial Officer. The company will issue a news release announcing its first quarter 2018 financial results on Wednesday, May 2, 2018, prior to the conference call.
A live webcast of the conference call will also be available in the investor relations section of the company’s website at ir.conformis.com. The online archive of the webcast will be available on the company’s website for 30 days.
About ConforMIS, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. Conformis offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses approximately 420 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.
Contact
Investor Contact:
Oksana Bradley
[email protected]
(781) 374-5598
